Top Markets
Coin of the day
Beta Bionics, Inc. Beta Bionics, Inc.

Beta Bionics, Inc.

BBNX
株式のランク #10096
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated... Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
株価
$19.81
最終同期: 2026-08-28
時価総額
$891.32M
変化(1日)
1.39%
変化(1年)
5.16%
US
取引 Beta Bionics, Inc. (BBNX)

カテゴリー

Beta Bionics, Inc.(BBNX)のEPS
2026 時点のEPS TTM: 0
Beta Bionics, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Beta Bionics, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS